1.Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?.
Intestinal Research 2017;15(3):263-265
No abstract available.
Adalimumab*
2.A Case of SAPHO Presented with Venous Engorgement: Successful Treatment with Adalimumab.
Seongcheol CHO ; Eun Bong LEE ; Hyo Cheol KIM
Journal of Rheumatic Diseases 2016;23(1):76-77
No abstract available.
Adalimumab
;
Hyperemia*
3.Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?.
Joon Min JUNG ; Ye Jin LEE ; Chong Hyun WON ; Sung Eun CHANG ; Mi Woo LEE ; Jee Ho CHOI ; Kee Chan MOON
Annals of Dermatology 2015;27(5):620-621
No abstract available.
Vitiligo*
;
Adalimumab
4.Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?.
Joon Min JUNG ; Ye Jin LEE ; Chong Hyun WON ; Sung Eun CHANG ; Mi Woo LEE ; Jee Ho CHOI ; Kee Chan MOON
Annals of Dermatology 2015;27(5):620-621
No abstract available.
Vitiligo*
;
Adalimumab
5.Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis.
Jung Eun SEOL ; In Ho PARK ; Wonkyung LEE ; Hyojin KIM ; So Young JUNG ; Han Young WANG
Annals of Dermatology 2016;28(4):522-523
No abstract available.
Adalimumab*
;
Spondylitis, Ankylosing*
6.New-onset Psoriasis Induced by Adalimumab Administered for Rheumatoid Arthritis.
Hyun Yi SUH ; Kyung Ho KIM ; Ji Young AHN ; Mi Youn PARK ; Jai Il YOUN
Korean Journal of Dermatology 2017;55(7):480-482
No abstract available.
Adalimumab*
;
Arthritis, Rheumatoid*
;
Psoriasis*
7.Comparative Efficacy and Safety of Secukinumab and Adalimumab in Patients with Active Ankylosing Spondylitis: A Bayesian Network Meta-analysis of Randomized Controlled Trials.
Journal of Rheumatic Diseases 2017;24(4):211-219
OBJECTIVE: This study assessed the efficacy and safety of secukinumab and adalimumab in patients with active ankylosing spondylitis (AS). METHODS: A Bayesian network meta-analysis was performed with direct and indirect data collected from randomized controlled trials (RCTs) of efficacy and safety of secukinumab 75 mg, 150 mg and adalimumab 40 mg in patients with active AS. RESULTS: Five RCTs (1,483 patients) met the inclusion criteria. The Assessment in Spondyloarthritis International Society response criteria of ≥20% (ASAS20) response rate was significantly higher in the adalimumab 40 mg (Odds ratio [OR], 4.26; 95% credible interval [CrI], 2.09~8.08), secukinumab 150 mg (OR, 3.35; 95% CrI, 1.73~6.56), and 75 mg dose (OR, 2.44; 95% CrI, 1.06~5.05) than with placebo. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that adalimumab 40 mg had the highest probability of being the best treatment for achieving an ASAS20 response (SUCRA=0.8753), followed by secukinumab 150 mg (SUCRA=0.7051), secukinumab 75 mg (SUCRA=0.4113), and placebo (SUCRA=0.0083). The ASAS40 response rate distribution pattern was similar to the ASAS20 response rate. However, the number of serious adverse events did not differ significantly among the treatment options. CONCLUSION: Secukinumab and adalimumab were effective for the treatment of active AS without causing a significant risk of serious adverse events.
Adalimumab*
;
Humans
;
Spondylitis, Ankylosing*
8.Reversible Corpus Callosal Lesions Associated with the Use of Adalimumab for Ulcerative Colitis.
Jin Woo PARK ; Hung Yuol SEOK ; Yoohwan KIM ; Byung Jo KIM
Journal of Clinical Neurology 2017;13(2):209-211
No abstract available.
Adalimumab*
;
Colitis, Ulcerative*
;
Ulcer*